These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 21757251)

  • 21. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY; Zhao HY; Zhou N; Zhou F; Li PP
    J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
    Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J
    Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
    Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
    Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
    Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB
    J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
    Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
    PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP
    Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Sordella R; Bell DW; Haber DA; Settleman J
    Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
    Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
    Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
    Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
    Kobayashi S; Ji H; Yuza Y; Meyerson M; Wong KK; Tenen DG; Halmos B
    Cancer Res; 2005 Aug; 65(16):7096-101. PubMed ID: 16103058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.